In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned the abstracts and companies he would be tracking during the upcoming AAIC.
This could include aducanumab by Biogen Inc BIIB and solanezumab by Eli Lilly and Co LLY.
AAIC is scheduled between July 18 and 22. Analyst Mark Schoenebaum noted the planner for abstracts that they would be will be tracking:
Saturday - July 18
- POSTER
Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Exhibit Hall E
IC-P-030
12:15pm - 2:15pm
Tuesday - July 21
- POSTER
Safety of Solanezumab in the Expedition-EXT Study up to 2 Years in a Mild to Moderate Alzheimer's Disease Population
Exhibit Hall D
P3-285
9:30am - 4:15pm
- ORAL
Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Hall E
03-01-04
2:00pm - 3:30pm
Wednesday – July 22
- ORAL
Delayed-Start Analyses of up to 3.5 Years in the Phase 3 Solanezumab Expedition Program in Mild Alzheimer's Disease
Ballroom A
04-03-02
8:00am - 9:30am
- POSTER
Rvt-101, a 5-HT6 Receptor Antagonist, As Adjunctive Therapy with Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Responder Analysis
Exhibit Hall E
P4-302
9:30am - 4:15pm
- ORAL
Aducanumab (BIIB037), an Anti-Amyloid Beta Monoclonal Antibody, in Patients with Prodromal or Mild Alzheimer's Disease: Interim Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1B Study
146
04-04-05
2:00pm - 3:30pm
- ORAL
The Efficacy of Rvt-101, a 5-HT6 Receptor Antagonist, As an Adjunct to Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Completer Analysis of a Phase 2b Study
Hall E
DT-01-04
2:00pm - 3:30pm
- Axovant Investor Briefing
Doors open at 5:15pm
Presentation begins 5:45pm
Marriott Marquis, Georgetown Room, 900 Massachusetts Ave. Northwest, Washington, DC 20001
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.